RESUMEN
Multi-dose dry powder inhalers (DPIs) are commonly used in asthma and chronic obstructive lung disease (COPD) treatment. A disadvantage is their sensitivity to humidity. In real life, DPIs are periodically exposed to humid conditions, which may affect aerosol characteristics and lung deposition. This study compared DPI aerosol performance after exposure to humidity. Budesonide (BUD) inhalers (Turbuhaler; Novolizer; Easyhaler) and budesonide/formoterol (BUD/FORM) inhalers (Turbuhaler; Spiromax; Easyhaler) were stored in 75% relative humidity (RH) at both ambient temperature and at -0 °C. Delivered dose (DD) and fine-particle dose (FPD) were tested in vitro before and after storage. BUD inhalers: Turbuhaler and Novolizer showed only small decreases (<15%) in FPD in 40 °C/75% RH, whereas FPD for Easyhaler decreased by >60% (P=0.01) after 1.5 months of storage. Easyhaler also decreased significantly after 6 months of storage in ambient/75%RH by 25% and 54% for DD and FPD, respectively, whereas only small decreases were seen for Turbuhaler and Novolizer (<15%). BUD/FORM inhalers: Turbuhaler and Spiromax DD were unchanged in 40 °C/75% RH, whereas Easyhaler showed a small decrease. FPD (budesonide) decreased for Turbuhaler, Spiromax and Easyhaler by 18%, 10% and 68% (all significant), respectively, at 40 °C/75% RH. In ambient/75%RH, DD was unchanged for all inhalers, whereas FPD (budesonide) decreased for Spiromax (7%, P=0.02) and Easyhaler (34%, (P<0.01)). There are significant differences in device performance after exposure to humid conditions. A clinically relevant decrease of more than half FPD was seen for one of the inhalers, a decrease that may affect patients' clinical outcomes. Prescriber and patient knowledge on device attributes are essential to ensure optimal drug delivery to the lungs.
Asunto(s)
Antiasmáticos/administración & dosificación , Combinación Budesonida y Fumarato de Formoterol/administración & dosificación , Budesonida/administración & dosificación , Inhaladores de Polvo Seco , Humedad , Administración por Inhalación , Asma/tratamiento farmacológico , Humanos , Técnicas In Vitro , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológicoRESUMEN
BACKGROUND: Cyclosporine (CsA) absorption varies early after transplantation and can be accurately assessed by the area under the absorption curve (AUC). The 2-hour post-dose (C2) level of CsA in whole blood is reported to be a useful surrogate marker of CsA AUC in kidney and liver transplant monitoring, but should be further explored in thoracic organ recipients. METHODS: In a 12-month study we included de novo lung (n = 95) and heart (n = 96) recipients. All participants received cyclosporine (Sandimmun Neoral) monitored by C0 and blood was collected for analysis of C2 retrospectively. Abbreviated AUC (AUC(0-4)) was measured at 7 days and 3 months. Primary outcome was C2 relation to the frequency of acute cellular rejection (ACR) needing treatment and possible decline in measured glomerular filtration rate (mGFR). Recipients were divided into lower, middle and upper third C2 groups based on 2-week post-operative values (tertiles T1 to T3). RESULTS: C2 was the most robust substitute for AUC(0-4) in the group of patients studied. For lung, but not heart, recipients there were differences in mean number of ACRs (p = 0.05), incidence of any rejections (p = 0.04), mean number of any rejections (p = 0.001) and time to first rejection (p = 0.03) between T1 and T3. C2 did not predict reduction in mGFR. CONCLUSIONS: C2 is a sensitive predictor for ACR in lung, but not heart, recipients, C2 was not predictive of a decline in mGFR. This study suggests that management of lung recipients by C2 may diminish the number of ACRs.
Asunto(s)
Ciclosporina/sangre , Ciclosporina/uso terapéutico , Rechazo de Injerto/inmunología , Trasplante de Corazón/inmunología , Trasplante de Pulmón/inmunología , Adulto , Área Bajo la Curva , Presión Sanguínea , Cardiomiopatías/cirugía , Enfermedad de la Arteria Coronaria/cirugía , Creatinina/sangre , Ciclosporina/farmacocinética , Fibrosis Quística/cirugía , Enfisema/cirugía , Femenino , Tasa de Filtración Glomerular , Rechazo de Injerto/epidemiología , Trasplante de Corazón/mortalidad , Humanos , Inmunosupresores/sangre , Inmunosupresores/farmacocinética , Inmunosupresores/uso terapéutico , Trasplante de Pulmón/mortalidad , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico/métodos , Enfermedad Pulmonar Obstructiva Crónica/cirugíaAsunto(s)
Enfermedades Pulmonares/cirugía , Trasplante de Pulmón , Adulto , Factores de Edad , Anciano , Contraindicaciones , Femenino , Trasplante de Corazón-Pulmón/estadística & datos numéricos , Humanos , Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/mortalidad , Trasplante de Pulmón/mortalidad , Trasplante de Pulmón/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Suecia/epidemiología , Resultado del TratamientoAsunto(s)
Trasplante de Corazón , Adolescente , Adulto , Anciano , Niño , Preescolar , Competencia Clínica , Femenino , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/cirugía , Trasplante de Corazón/efectos adversos , Trasplante de Corazón/mortalidad , Trasplante de Corazón/normas , Trasplante de Corazón/estadística & datos numéricos , Humanos , Lactante , Masculino , Persona de Mediana Edad , Evaluación de Resultado en la Atención de Salud , Complicaciones Posoperatorias/etiología , Complicaciones Posoperatorias/mortalidad , Tasa de Supervivencia , Suecia/epidemiología , Adulto JovenRESUMEN
BACKGROUND: The presence of mild to moderate ischemic mitral regurgitation (IMR) marks a significantly reduced long-term survival and increased hospitalizations due to heart-failure. However, it is common practice in many institutions to refrain from repairing the mitral valve in these patients. There are no available conclusive data to support this practice, and thus there is a need for an adequately powered randomized trial. STUDY DESIGN: The Moderate Mitral Regurgitation In Patients Undergoing CABG (MoMIC) trial is the first international multi-center, large-scale study to clarify whether moderate IMR in CABG patients should be corrected. A total of 550 CABG patients with moderate IMR are to be randomized to treatment of either CABG alone or CABG plus mitral valve correction. The primary end point is a composite end point of mortality and rehospitalization for heart failure at five years. The inclusion and randomization of patients started in February 2008. IMPLICATION: If correction of moderate IMR in CABG patients proves to be the superior strategy, most patients should be treated accordingly.
Asunto(s)
Puente de Arteria Coronaria , Enfermedad de la Arteria Coronaria/cirugía , Insuficiencia de la Válvula Mitral/cirugía , Isquemia Miocárdica/cirugía , Implantación de Prótesis Vascular , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/mortalidad , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/mortalidad , Hospitalización , Humanos , Insuficiencia de la Válvula Mitral/etiología , Insuficiencia de la Válvula Mitral/mortalidad , Isquemia Miocárdica/etiología , Isquemia Miocárdica/mortalidad , América del Norte , Proyectos de Investigación , Países Escandinavos y Nórdicos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVE: The aim of this study was to determine the prevalence of moderate ischemic mitral regurgitation (IMR) in the contemporary CABG population. We also aimed to correlate the effective regurgitant orifice area (ERO) of any regurgitant mitral valve in patients with coronary artery disease with the semiquantitative integrated scale of IMR. DESIGN: From March 15 through June 15, 2006, 510 consecutive CABG patients in three tertiary centres were included in the study. All patients showing any sign of mitral regurgitation (MR) at the referring hospital underwent a preoperative transthoracic echocardiographic estimation of the degree of MR using the integrated scale (1-4) and ERO. RESULTS: IMR was found in 141 patients (28%). The prevalence of moderate 2+ or worse IMR was 4% (95% CI; 2.5-6.1%) and the ERO corresponding to 2+ IMR or more ranged from 5 to 30 mm(2). Fourteen patients had an ERO between 15-30 mm(2). CONCLUSIONS: According to our study, patients with moderate IMR, defined as an ERO between 15-30 mm(2), account for only 2.7% (95% CI; 1.5-4.7%) of a non-emergency CABG population.
Asunto(s)
Puente de Arteria Coronaria , Enfermedad de la Arteria Coronaria/cirugía , Insuficiencia de la Válvula Mitral/etiología , Isquemia Miocárdica/etiología , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/epidemiología , Dinamarca/epidemiología , Humanos , Insuficiencia de la Válvula Mitral/diagnóstico por imagen , Insuficiencia de la Válvula Mitral/epidemiología , Insuficiencia de la Válvula Mitral/cirugía , Isquemia Miocárdica/epidemiología , Isquemia Miocárdica/cirugía , Prevalencia , Índice de Severidad de la Enfermedad , Suecia/epidemiología , UltrasonografíaRESUMEN
Anemia of inflammation in patients with acute or chronic acute-phase activation is a common clinical problem. Hepcidin is a peptide shown to be the principal regulator of the absorption and systemic distribution of iron. Main inducers of hepcidin are iron overload, hypoxia and inflammation, where the latter has been linked to hepcidin via increased interleukin-6 (IL-6). This article addresses the impact and time course of postoperative acute-phase reaction in humans following heart surgery on prohepcidin, hepcidin, hematological markers and IL-6 concentrations. Serum concentrations of prohepcidin, hepcidin, IL-6 and hematological iron parameters were studied in five male patients without infection before and after heart surgery. This study, which is the first to report the impact on serum hepcidin and serum prohepcidin concentrations in patients following surgery, clearly demonstrates the induction of hypoferremia due to the postoperative acute-phase reaction. Significant changes were seen for serum iron concentration, transferrin saturation, total iron binding capacity and hemoglobin concentration. A significant increase in ferritin concentration was seen 96-144 h postoperatively. Additionally, there were significant alterations in both serum hepcidin after 96-144 h and serum prohepcidin after 48 h compared with preoperative values. Serum prohepcidin decreased, whereas serum hepcidin increased. In conclusion, changes in serum prohepcidin were followed by an increase in serum hepcidin. This speaks in favor of a chain of action where proteolytic trimming of serum prohepcidin results in increased serum hepcidin. However, hypoferremia appeared prior to the changes in serum prohepcidin and serum hepcidin.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/biosíntesis , Cardiopatías/sangre , Cardiopatías/cirugía , Hematología/métodos , Interleucina-6/biosíntesis , Hierro/metabolismo , Cirugía Torácica/métodos , Reacción de Fase Aguda , Anciano , Ferritinas/sangre , Hemoglobinas/biosíntesis , Hepcidinas , Humanos , Inflamación , Hierro/sangre , Masculino , Factores de Tiempo , Resultado del TratamientoRESUMEN
A 38-year-old man with progressive alveolitis secondary to polymyositis was treated for 52 days with venovenous and venoarterial extracorporeal membrane oxygenation as a bridge to bilateral lung transplantation. The patient survived, despite multiple complications, and is now back home with good pulmonary function. He is working part-time nearly 3 years post-transplant. This case shows that long-term extracorporeal lung assist is a viable but demanding alternative for bridging patients to pulmonary transplantation. This case also shows that right ventricular failure necessating conversion to veno-arterial assist does not necessarily predict right ventricular failure post-transplant.
Asunto(s)
Dermatomiositis/complicaciones , Oxigenación por Membrana Extracorpórea/métodos , Insuficiencia Respiratoria/terapia , Listas de Espera , Adulto , Dermatomiositis/diagnóstico , Progresión de la Enfermedad , Estudios de Seguimiento , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/terapia , Hemodinámica/fisiología , Humanos , Trasplante de Pulmón/métodos , Masculino , Fibrosis Pulmonar/etiología , Fibrosis Pulmonar/cirugía , Insuficiencia Respiratoria/etiología , Medición de Riesgo , Factores de Tiempo , Resultado del TratamientoRESUMEN
Lung transplantation (LTx) is a therapeutic option for patients with end-stage lung disease. However, the mortality rate of patients on the waiting list is high. The purpose of this study was to examine the prognostic value of cardio-pulmonary hemodynamics for death in patients awaiting LTx. Retrospectively, 177 patients with advanced lung disease accepted for LTx at Sahlgrenska University Hospital from January 1990 through December 2003 were studied. Patient demographics, pulmonary function tests, gas exchange and hemodynamic variables were included in the analysis. Death while awaiting LTx was the primary endpoint for all analyses. Mean age was 49 +/- 9 years. Main diagnoses were alpha 1 antitrypsin deficiency (n = 56), chronic obstructive pulmonary disease (n = 61), cystic fibrosis (n = 14) and interstitial lung disease (n = 46). Thirty patients died (17%). LTx was performed in 143 cases. By univariate analyses, forced vital capacity (FVC) % of predicted, pulmonary vascular resistance (PVR) and diagnosis were associated with risk for death. In multivariate analysis PVR (HR, 1.22; 95% CI, 1.06-1.41; P = 0.006) and FVC% of predicted (HR, 0.97; 95% CI, 0.94-0.99; P = 0.01) were independently associated with death. Patients with increased PVR and a lower FVC % of predicted awaiting LTx should be considered for a higher organ allocation priority. Assessment of pulmonary hemodynamics needs to be considered during evaluation for LTx.
Asunto(s)
Enfermedades Pulmonares/diagnóstico , Enfermedades Pulmonares/mortalidad , Trasplante de Pulmón/mortalidad , Pulmón/fisiopatología , Adulto , Femenino , Hemodinámica , Humanos , Enfermedades Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pruebas de Función Respiratoria , Factores de Riesgo , Índice de Severidad de la Enfermedad , Factores de Tiempo , Listas de EsperaRESUMEN
OBJECTIVE: To investigate the relationship between ASAT, CKMB, troponin-T and mortality after cardiac surgery. DESIGN: ASAT, CKMB and TnT were analysed in 116 patients. Correlation, sensitivity, specificity and predictive values for permanent myocardial injury (defined as TnT > or = 2.0 microg/l postoperative day four) were calculated. In the second part our clinical protocol (ASAT on postoperative day 1 and TnT on day 3-4 in patients with ASAT above 2.5 microkat/l) was evaluated. Mortality was compared between patients with ASAT < 2.5 microkat/l (ASAT-), 2. ASAT > or = 2.5 microkat/l and TnT < 2.0 microg/l (ASAT+/TnT-) and 3. ASAT > or = 2.5 microkat/l and TnT > or = 2.0 microg/l (ASAT+/TnT+). RESULTS: Both ASAT and CKMB had irrespectively of cut-off level, low positive and high negative predictive value of permanent myocardial injury. Early and mid-term mortality did not differ significantly between ASAT- and ASAT+/TnT- patients. CONCLUSIONS: ASAT and CKMB can be used to exclude but not to diagnose permanent myocardial injury after cardiac surgery. Increased postoperative ASAT in the absence of increased TnT is not associated with worse clinical outcome than after normal postoperative ASAT.
Asunto(s)
Aspartato Aminotransferasas/sangre , Biomarcadores/sangre , Procedimientos Quirúrgicos Cardíacos/mortalidad , Forma MB de la Creatina-Quinasa/sangre , Miocardio/patología , Anciano , Femenino , Cardiopatías/cirugía , Humanos , Masculino , Persona de Mediana Edad , Isquemia Miocárdica/sangre , Isquemia Miocárdica/patología , Periodo Posoperatorio , Estudios Retrospectivos , Sensibilidad y Especificidad , Troponina TAsunto(s)
Instituciones Cardiológicas/normas , Trasplante de Corazón/mortalidad , Trasplante de Hígado/mortalidad , Calidad de la Atención de Salud , Seguridad , Instituciones Cardiológicas/estadística & datos numéricos , Trasplante de Corazón/normas , Trasplante de Corazón/estadística & datos numéricos , Humanos , Trasplante de Hígado/normas , Trasplante de Hígado/estadística & datos numéricos , Reino UnidoRESUMEN
OBJECTIVE: To study the achievability of device weaning in patients receiving left ventricular assist devices (LVADs) as a bridge to transplantation. METHODS: Eighteen consecutive patients receiving a LVAD between September 1997 and June 2002 were included in the study. During a four-month follow-up, patients were repeatedly evaluated with right heart catheterization and echocardiography and, if functional improvement was observed, studied with the device turned off. Cardiac recovery was defined as off-pump LVEF>or=40% together with a significant improvement in invasive haemodynamic measurements (CI>or=2.5 and PCWPAsunto(s)
Insuficiencia Cardíaca/fisiopatología
, Insuficiencia Cardíaca/cirugía
, Corazón Auxiliar
, Recuperación de la Función
, Adulto
, Cateterismo Cardíaco
, Cardiomiopatía Dilatada/complicaciones
, Cardiomiopatía Dilatada/fisiopatología
, Cardiomiopatía Hipertrófica/complicaciones
, Cardiomiopatía Hipertrófica/fisiopatología
, Ecocardiografía Doppler
, Prueba de Esfuerzo
, Estudios de Factibilidad
, Femenino
, Estudios de Seguimiento
, Insuficiencia Cardíaca/etiología
, Trasplante de Corazón
, Humanos
, Masculino
, Persona de Mediana Edad
, Isquemia Miocárdica/complicaciones
, Isquemia Miocárdica/fisiopatología
, Miocarditis/complicaciones
, Miocarditis/fisiopatología
, Estudios Prospectivos
, Volumen Sistólico
, Suecia/epidemiología
, Resultado del Tratamiento
RESUMEN
The majority of patients undergoing solid organ transplantation develop hypertension, to which vasoconstriction and impaired endothelial function have been suggested to contribute. We compared basal vascular resistance and nitric oxide-mediated endothelial-dependent and independent vasoreactivity between cyclosporine-treated lung transplant recipients and healthy subjects. Forearm blood flow was measured by venous occlusion plethysmography at rest and during acetylcholine, glyceryltrinitrate and N(G)-monomethyl-L-arginine acetate (L-NMMA) infusion in 11 lung transplant recipients 3-5 years after transplantation and in eight healthy subjects. Forearm vascular resistance (FVR) was calculated. Plasma levels of endothelin-1 (ET-1) and von Willebrand factor (vWf) were analysed. Basal vascular resistance was 40% lower in transplant recipients than in healthy subjects (P = 0.021). Endothelial-dependent and independent vasodilation did not differ. Plasma levels of ET-1 and vWf were higher in transplant recipients (P = 0.009 and P < 0.001 respectively). There was a significant correlation between ET-1 levels and FVR in healthy subjects (r = 0.83, P = 0.042), but not in transplant recipients (r = -0.14, P = 0.70). The findings oppose the theory of generalized vasoconstriction and impaired endothelial function in the pathogenesis of hypertension after transplantation. Increased plasma levels of ET-1 do not cause increased FVR in lung transplant recipients.
Asunto(s)
Ciclosporina/uso terapéutico , Células Endoteliales/fisiología , Trasplante de Pulmón , Resistencia Vascular , Adulto , Antígenos/análisis , Presión Sanguínea , Endotelina-1/sangre , Femenino , Frecuencia Cardíaca , Humanos , Trasplante de Pulmón/efectos adversos , Masculino , Persona de Mediana Edad , Óxido Nítrico/fisiología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Factor de von Willebrand/inmunologíaAsunto(s)
Capacidad de Camas en Hospitales , Hospitales de Condado , Asignación de Recursos para la Atención de Salud , Política de Salud , Capacidad de Camas en Hospitales/estadística & datos numéricos , Hospitales de Condado/estadística & datos numéricos , Hospitales de Condado/tendencias , Humanos , SueciaRESUMEN
BACKGROUND: Only a minority of the potential candidates for lung donation are considered suitable, using current evaluation methods. A new method for ex vivo evaluation, with the potential for reconditioning of marginal and nonacceptable lungs, has been developed. This is a report of the ex vivo evaluation of six donor lungs deemed nonacceptable (arterial oxygen pressure less than 40 kPa) by the Scandiatransplant, Eurotransplant, and UK transplant organizations. METHODS: The lungs are perfused ex vivo with Steen solution, a lung evaluation-preservation solution, mixed with red blood cells to a hematocrit of 15%. This extracellular solution is designed to have an optimal colloid osmotic pressure so that physiologic pressure and flow can be maintained without development of pulmonary edema. An oxygenator connected to the extracorporeal circuit maintains a normal mixed venous blood gas level in the perfusate. The lungs are ventilated and evaluated through analyses of pulmonary vascular resistance, oxygenation capacity, and arterial carbon dioxide pressure minus end-tidal carbon dioxide difference. RESULTS: The arterial oxygen pressure (inspired oxygen fraction, 1.0) increased from 27 kPa (range, 17 to 34 kPa) in situ in the organ donor at the referring hospital to 57 kPa (range, 39 to 66 kPa) during the ex vivo evaluation. The pulmonary vascular resistance varied from 3.2 to 5.7 Wood units, and the arterial carbon dioxide pressure minus end-tidal carbon dioxide difference was in the range of 1 to 2.5 kPa. CONCLUSIONS: The arterial oxygen pressure improves significantly in this model. This ex vivo evaluation model is a valuable addition to the armamentarium in finding acceptable lungs in a donor population with inferior arterial oxygen pressure values.
Asunto(s)
Trasplante de Pulmón , Pulmón/fisiología , Oxígeno/análisis , Donantes de Tejidos , Dióxido de Carbono/análisis , Humanos , Isquemia , Pulmón/irrigación sanguínea , Modelos Teóricos , Óxido Nítrico/administración & dosificación , Valores de Referencia , Reperfusión , Resistencia VascularRESUMEN
Preoperative prediction of a successful outcome following lung volume reduction surgery (LVRS) for emphysema is imperfect. One mechanism could be improvement in respiratory muscle function yet controversy exists regarding the magnitude and mechanism of such an improvement. Therefore, we measured diaphragm strength in 18 patients before and after LVRS. Mean (S.D.) FRC fell from 6.53 to 5.40 l (p = 0.0001). Mean sniff transdiaphragmatic pressure increased from 76 to 87 cm H2O (14%, p < 0.03) and mean twitch transdiaphragmatic pressure (Tw Pdi) increased by 2.5 cm H2O at 3 months (12%, p = 0.03). There was a highly significant increase in twitch esophageal pressure (Tw Pes) (60%, p < 0.0001), which was maintained at 12 months (46% increase, p = 0.0004). No change was observed in quadriceps twitch tension in nine subjects in whom it was measured. After LVRS the ratio Tw Pes:Tw Pdi increased from 0.24 to 0.37 at 3 months (p = 0.0003) and 0.36 at 12 months (p = 008). Low values of Sn Pdi, Sn Pes, Tw Pes and a high RV/TLC ratio were the preoperative variables most predictive of improvement in shuttle walking distance. We conclude that LVRS improves diaphragm function primarily by alteration of lung volume. Patients with poor diaphragm function and high RV/TLC ratio preoperatively are most likely to benefit from the procedure.
Asunto(s)
Diafragma/fisiopatología , Pulmón/cirugía , Enfisema Pulmonar/cirugía , Adulto , Anciano , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado/fisiología , Humanos , Masculino , Persona de Mediana Edad , Contracción Muscular/fisiología , Presión Parcial , Enfisema Pulmonar/fisiopatología , Espirometría/métodos , Estadísticas no Paramétricas , Factores de Tiempo , Capacidad Pulmonar Total/fisiología , Capacidad Vital/fisiologíaRESUMEN
STUDY OBJECTIVES: In 1996, researchers in Sweden initiated a collaborative randomized study comparing lung volume reduction surgery (LVRS) and physical training with physical training alone. The primary end point was health status; secondary end points included survival and physiologic measurements. DESIGN: After an initial 6-week physical training program, researchers' patients were randomized to either LVRS (surgical group [SG]) with continued training for 3 months, or to continued training alone (training group [TG]) for 1 year. SETTING: All seven thoracic surgery centers in Sweden. PATIENTS: All patients in Sweden with severe emphysema fulfilling inclusion criteria for LVRS. INTERVENTIONS: Patients randomized to surgery underwent a median sternotomy, except for a few patients in whom thoracotomy or video-assisted thoracoscopy were performed. In the TG, supervised physical training continued for 1 year; in the SG, supervised physical training continued for 3 months postoperatively. MEASUREMENTS AND RESULTS: Fifty-three patients were included in each group. Six in-hospital deaths occurred after surgery (12%), and one more death occurred during follow-up. Two deaths occurred in the TG. The difference in death rates between the groups was not statistically significant. Health status, as measured by St. George Respiratory Questionnaire (SGRQ) [total scale score mean difference at 1 year, 14.7; 95% confidence interval (CI), 9.8 to 19.7] as well as by the Medical Outcomes Study Short-Form General Health Survey (physical function scale score mean difference at 1 year, 19.7; 95% CI, 12.1 to 27.3) was improved from baseline in the SG compared with the TG. FEV(1), residual volume, and shuttle walking test values also improved in the SG but not in the TG after 6 months and 12 months. CONCLUSIONS: In severe emphysema, LVRS can improve health status in survivors but is associated with mortality risk. The effects are stable for at least 1 year. Physical training alone failed to achieve a similar improvement.
Asunto(s)
Terapia por Ejercicio , Estado de Salud , Neumonectomía , Enfisema Pulmonar/cirugía , Tolerancia al Ejercicio , Femenino , Indicadores de Salud , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función RespiratoriaRESUMEN
BACKGROUND: Cardiovascular disease (CVD) is a common cause of morbidity and mortality after solid-organ transplantation. Both pre-existing cardiovascular risk factors in recipients and immunosuppressive drug toxicity may contribute to CVD. We sought to describe the prevalence of new-onset hypertension, hypercholesterolemia and diabetes mellitus in lung transplant recipients and to identify predisposing factors. METHODS: One hundred twenty-six patients without pre-transplant hypertension, hypercholesterolemia or diabetes were included in a retrospective descriptive study. All patients were initially on cyclosporine-based triple immunosuppression. Cumulative prevalence of new-onset hypertension, hypercholesterolemia and diabetes were calculated. A multivariate Cox regression model was used to identify independent pre-operative predictors. RESULTS: By 3 years after transplantation, 90% of patients had developed at least 1 cardiovascular risk factor and 40% developed > or = 2 risk factors. The cumulative prevalence of new-onset hypertension at 1, 3, 5 and 7 years was 45%, 65%, 67% and 72%, respectively. The corresponding prevalence for hypercholesterolemia was 16%, 33%, 48% and 58%, and for diabetes 6%, 7%, 7% and 10%, respectively. The independent pre-transplant predictors were: for hypertension, diastolic blood pressure (odds ratio: 2.1 per 10 mm Hg [95% confidence interval: 1.3 to 3.5], p = 0.005); for hypercholesterolemia, serum cholesterol level (OR: 1.8 per mmol/liter [95% CI: 1.3 to 2.5], p < 0.001); and, for diabetes, cystic fibrosis diagnosis (OR: 7.4 [95% CI: 1.6 to 35.6], p = 0.01) and blood glucose level (OR 2.2 per mmol/liter [95% CI 1.1 to 4.5], p = 0.02). CONCLUSIONS: The majority of cyclosporine-treated lung transplant recipients develop new-onset hypertension or hypercholesterolemia early after transplantation. Pre-transplant blood pressure, serum cholesterol levels and blood glucose levels are independent predictors of post-transplant hypertension, hypercholesterolemia and diabetes, respectively.
Asunto(s)
Diabetes Mellitus/etiología , Hipercolesterolemia/etiología , Hipertensión/etiología , Inmunosupresores/efectos adversos , Trasplante de Pulmón/efectos adversos , Adulto , Causalidad , Diabetes Mellitus/diagnóstico , Femenino , Estudios de Seguimiento , Trasplante de Corazón/efectos adversos , Humanos , Hipercolesterolemia/diagnóstico , Hipertensión/diagnóstico , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Insuficiencia Respiratoria/cirugía , Estudios Retrospectivos , Factores de Riesgo , TrasplanteRESUMEN
BACKGROUND: The majority of cyclosporine-treated transplant recipients develop hypertension. Endothelin-1 (ET-1) has been suggested to mediate cyclosporine-induced vasoconstriction when binding to ET-A receptors. We hypothesized that cyclosporine-treated lung transplant recipients have an increased basal vascular resistance and an augmented response to ET-A receptor blockade. METHODS: The selective ET-A receptor blocker BQ-123 (10 and 50 nmol/min) was infused into the brachial artery, alone or in combination with the nitric oxide synthase inhibitor NG-monomethyl-L-arginine acetate (L-NMMA) (2 and 4 micromol/min) in 10 lung transplant recipients without pharmacologically treated hypertension and 8 healthy controls. Forearm blood flow (FBF) was measured by venous occlusion plethysmography and plasma levels of ET-1 were analyzed. RESULTS: Baseline forearm vascular resistance did not differ between recipients and controls (32 +/- 4 vs 42 +/- 7 mmHg/ml/min, p = 0.32). BQ-123 increased FBF in controls but not in recipients (26% +/- 9% vs 5% +/- 11% at 10 nmol/min, p = 0.043 between groups). Coinfusion of BQ-123 and L-NMMA caused a comparable decrease in FBF in recipients and controls (-26% +/- 11%, vs -34% +/- 7%). Baseline ET-1 was higher in recipients (17.2 +/- 1.1 vs 14.7 +/- 0.8 pg/ml, p = 0.038). BQ-123 infusion increased plasma ET-1 in controls but not in recipients (+24% +/- 11% vs -0.4% +/- 6.2%, p = 0.029 between groups). CONCLUSIONS: The results demonstrate that cyclosporine-treated lung transplant recipients have increased plasma levels of ET-1 and a blunted response to ET-A receptor blockade compared with healthy subjects. In contrast, we found no evidence for an increased basal vascular resistance in transplant recipients. These alterations in endothelin handling may contribute to the development of transplant-associated hypertension.